argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 feb 2015 - 07:24
Statutaire naam
argenx SE
Titel
Lonza and arGEN-X Announce a Multi-product GS Xceed(TM) License Agreement for Therapeutic Antibodies
Bericht
Basel, Switzerland, Ghent, Belgium and Breda, The Netherlands, 18 Feb 2015 - Lonza, a global leader in biological manufacturing and arGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X's therapeutic antibodies. The license secures long-term access for arGEN-X and its strategic partners to Lonza's proprietary GS Xceed(TM) System for creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals.
Datum laatste update: 29 januari 2026